Emerald Health Pharmaceuticals to Present Preclinical Data on EHP-101 for the Treatment of Multiple Sclerosis and Scleroderma at the 28th Annual Symposium of the International Cannabinoid Research Society
SAN DIEGO, CA / ACCESSWIRE / June 29, 2018 /Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, will present preclinical data on EHP-101, a patented synthetic cannabidiol (CBD)-derived new chemical entity (NCE), for the treatment of multiple sclerosis (MS) and scleroderma (SSc). A presentation and poster session will occur at the upcoming 28th Annual Symposium of the International Cannabinoid Research Society to be held on July 1- 4, 2018 in Leiden, Netherlands.
Details of the oral presentation are as follows:
Abstract Title:Effect of Oral VCE-004.8, A Cannabidiol Quinol Derivative On Experimental Autoimmune Encephalomyelitis
Lead Author: Carmen Navarrete, Ph.D.
Date and Time:July 3, 2018 at 9:30 AM CET
Location:Leidse Schouwburg Stadsgehoorzaal
Details of the poster session are as follows:
Abstract Title:Oral EHP-101 Alleviates Skin and Lung Fibrosis in Bleomycin Model of Scleroderma
Lead Author:Adela Garcia, Ph.D.
Date and Time:July 2, 2018 at 3:00 - 5:00 PM CET
Location:Leidse Schouwburg Stadsgehoorzaal
For more information about this conference, please visit: http://www.icrs2018.org/.
EHP-101, also known in the scientific literature as VCE-004.8, is a patented aminoquinone NCE derived from CBD. It has been modified to enhance the therapeutic benefits of CBD by having a dual PPARγ and CB2 agonist activity, and also by affecting the hypoxia inducible factor (HIF) pathway. These receptors have been shown in the scientific literature to be beneficial in preventing neuroinflammation and demyelination in the central nervous system, and fibrogenesis in the periphery. EHP acquired VCE-004.8 from Vivacell Biotechnology España S.L. (Vivacell), a world leader in cannabinoid science located in Córdoba, Spain
About Emerald Health Pharmaceuticals Inc.
Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The Company has two families of new chemical entities, based on CBD and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating MS and SSc. Its second, EHP-102, is focused on treating Huntington's disease and Parkinson's disease. The company is advancing preclinical development with the intent to launch a Phase I clinical study in 2018. For more information, visit www.emeraldpharma.life or contact: email@example.com.
To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.
SOURCE:Emerald Health Pharmaceuticals
© 2018 Accesswire. All Rights Reserved.
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services